News
New streamlined NGS library preparation for using Diagenode’s Bioruptor® and the Bioline JetSeq® Flex DNA Library Preparation Kit
November 6, 2017
Diagenode and Bioline today announced a newly developed, streamlined solution for DNA library preparation prior to next generation sequencing combining the JetSeq® Flex DNA Library Preparation Kit and the Diagenode Bioruptor® sonication system.
The Bioline JetSeq Flex DNA Library Preparation Kit is based on proprietary technology that contains optimized buffer systems to create high quality libraries starting from a DNA input ranging between 1 ng and 1 µg, using any Illumina-compatible adapters. End-repair and ligation can be conducted in the same tube, reducing hands-on time and minimizes cross-contamination. In addition, the optional amplification step is carried out using a high fidelity Pfu-derived polymerase, ensuring low amplification bias.
The Bioruptor Pico from Diagenode represents a breakthrough as an all-in-one shearing system optimized for shearing micro-volumes of 5 μl to larger volumes of up to 2 ml. The Pico enables controlled and consistent shearing of up 16 samples simultaneously to produce DNA fragments within the optimal size range required for library preparation.
Marco Calzavara, President of Bioline commented, “We are excited to show with this Application Note how JetSeq Library Preparation Kit and Bioruptor Pico can efficiently complement each other in a simple and reliable workflow, giving to our customers a powerful solution in NGS library preparation”.
“We are pleased to present this combined workflow using the JetSeq and Bioruptor solutions,” said Jerome Kroonen, Strategic Marketing Manager at Diagenode. “Customers have access to a workflow for optimal library preparation that is both flexible and easy to use.”
In the two companies’ latest application note, the combined use of the Bioruptor Pico and JetSeq Flex DNA Library Preparation kit enabled production of high quality data with low duplication levels, low GC bias and a high percentage of unique mapping reads.
To learn more about --, please read the application note describing the workflows and resulting data.
To learn more about Bioline, please visit https://www.bioline.com
Diagenode:
Diagenode is a leading provider of complete solutions for epigenetics research and sample preparation. The company has developed both shearing solutions for a number of applications as well as a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative DNA and chromatin shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include the industry’s most validated ChIP antibodies, CATS-based RNA sequencing, ChIPmentation technology and epigenetics assay services. For more information about Diagenode, please visit the company’s website at www.diagenode.com.
Bioline:
Bioline, The PCR Company, is a wholly owned subsidiary of Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Its products are also used by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agri-bio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
